Physician profile
Alex E Baum
NPI 1962452615
$2,684.99
in general payments reported to CMS, 2019-2025
27 companies · $749 in 2025
The $749 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $45.43 · 2021: $113 · 2022: $512 · 2023: $410 · 2024: $455 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.95 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.94 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Genzyme Corporation | $275.93 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.81 | 2019-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $194.01 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.87 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $151.59 | 2024-2025 | Rezdiffra |
| Janssen Biotech, INC. | $133.39 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $131.72 | 2019-2024 | |
| Micro-Tech Endoscopy USA, INC. | $69.25 | 2024-2025 | Lesionhunter, Irrigation Tubing, Rapide Balloon |
| Celgene Corporation | $67.57 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $57.39 | 2022-2023 | |
| Meridian Bioscience INC. | $37.58 | 2022 | |
| Merck Sharp & Dohme LLC | $36.35 | 2023-2024 | Dificid |
| Vivus LLC | $34.96 | 2022-2024 | Qsymia |
| Ferring Pharmaceuticals INC. | $34.13 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $33.27 | 2021-2022 | |
| Ardelyx, INC. | $33.06 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $29.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.30 | 2024 | Cyltezo |
| Shionogi INC | $20.84 | 2019 | |
| Pharmacosmos Therapeutics INC. | $20.59 | 2022 | |
| Ethicon US, LLC | $20.21 | 2022 | |
| Lilly USA, LLC | $18.62 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $16.74 | 2025 | Voquezna |
| Amgen INC. | $16.67 | 2022 | |
| Concordia Pharmaceuticals INC. | $15.15 | 2019 | |
| Olympus America INC. | $14.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.